Orforglipron
Approved in the US (April 2026) and UK (August 2026).
A once-a-day pill with no food or water rules. It is not a peptide, and is here because it competes directly with the peptide drugs. A made by Eli Lilly, also called Foundayo.
What the evidence shows
Side effects and risks
Who should avoid it: Pregnancy, medullary thyroid cancer or MEN 2 in you or your family.
How it works
- Where it acts
- GLP-1 receptors, reached by a small molecule swallowed as a pill.
- What it changes
- More insulin when blood sugar is high, a slower stomach and fewer hunger signals.
- What people notice
- Less appetite and weight loss over months. Nausea and other stomach effects are common.
How it is taken
One tablet a day, at any time, with no food or water rules. Tablets run from 0.8 mg to 17.2 mg, and the dose is stepped up over months. A prescriber sets the schedule.
Getting it in the United States
The legal route for Orforglipron
Get a prescription from a licensed clinician. Fill it at a licensed pharmacy or through the maker's own direct service.
Manufacturer direct-to-patient platform
After FDA approval in 2026-04 the maker sold the pill through its own direct platform with home delivery, at about 149 dollars a month self-pay and from 25 dollars with commercial coverage. A prescription is still required.
Source: GLP1 Guide Substack, 2026-04
Retail pharmacies and telehealth prescribers
Retail pharmacy rollout began in 2026-04, and telehealth providers can prescribe it. Medicare Part D patients were due to pay about 50 dollars a month from 2026-07. Main risk is stopping early because of gut side effects.
Source: PharmaShots, 2026-04
Routes people use for any peptide in the United States
Telehealth prescribing
Online clinics prescribe after a questionnaire, sometimes with no live doctor visit, and mail the drug. FDA moved in February 2026 to restrict mass-marketed compounded copies and claims that they are generic equivalents.
Risk: Thin medical screening. Compounded versions are not reviewed by FDA for quality.
Covers: Approved GLP-1 drugs, compounded semaglutide and tirzepatide
Source: GZERO Media, Apr 2026
Clinical trial enrolment
The only lawful way to get an unapproved peptide drug with medical monitoring. ClinicalTrials.gov lists eligibility, sites and phone numbers. Researchers note recruitment is hard when people can buy the drug on the gray market instead of risking placebo.
Risk: Possible placebo assignment, strict eligibility and travel to a study site.
Covers: Investigational peptide drugs still in development
Source: NIH, finding a clinical trial
Routes people use for any peptide in the United States
Compounding pharmacy with prescription
A clinician prescribes and a pharmacy compounds. Twelve peptides left the FDA do-not-compound category in April 2026 and a panel backed six in July, but they are not yet formally eligible. Pharmaceutical-grade ingredient is scarce.
Risk: Legal status is unsettled until FDA rulemaking ends. Pharmacies may use research-grade ingredient.
Covers: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and similar
Source: Frier Levitt, Apr 2026
Med spas and weight-loss clinics
Very common. Secret shoppers called 75 clinics and med spas in two states after shortages ended. 92 percent offered compounded semaglutide and 87 percent tirzepatide, often mixed with B vitamins to look custom.
Risk: Four of 23 suppliers lacked sterile compounding licenses and four had disciplinary records.
Covers: Compounded semaglutide and tirzepatide
Source: American Med Spa Association on JAMA Health Forum study, Jul 2026
Concierge and longevity doctors
Cash-pay physicians build peptide plans for wealthy clients. Reporting from San Francisco says some source from overseas channels, domestic research-use-only sellers or the few compounding pharmacies that will supply clinicians.
Risk: A doctor's involvement does not guarantee a pharmaceutical-grade product.
Covers: BPC-157, thymosin alpha-1, Selank, Semax, CJC-1295, ipamorelin, retatrutide
Source: San Francisco Standard, Sep 2025
Cross-border purchase or import
FDA says importing drugs for personal use is illegal in most cases but it may not object to small personal quantities in limited situations. Reporting also describes people travelling to Mexico for injections.
Risk: Packages can be seized. Product origin and cold-chain handling are hard to check.
Covers: Approved prescription peptides sold abroad
Source: FDA, personal importation
Routes people use for any peptide in the United States
Research-chemical websites
Sites sell vials marked for research or not for human consumption, with no prescription. FDA says some ship direct to consumers with dosing directions, and it has sent warning letters. Retatrutide exists only through this route or trials.
Risk: Unknown identity, strength and sterility. No pharmacist or prescriber involved.
Covers: Retatrutide, semaglutide, tirzepatide, BPC-157 and most unapproved peptides
Source: FDA, unapproved GLP-1 drugs page
Direct orders from Chinese factories
Buyers message factory sales agents and pay by crypto or payment app. A minimum order of about ten vials pushes people to buy in bulk and share. A blockchain analysis found US buyers were the largest source of funds.
Risk: Many of the same vendors list fentanyl precursors. Lab reports sent by sellers cannot be verified.
Covers: GLP-1 copies, melanotan II, BPC-157, TB-500, GHK-Cu, epitalon
Source: TRM Labs, Oct 2026
Chat groups and social sellers
Dealers are found through Telegram, WhatsApp, Discord and influencer discount codes. In a May 2026 survey of 1,000 US users, 14.5 percent bought this way and three quarters asked an AI chatbot for dosing.
Risk: 45 percent of social media buyers in that survey reported an emergency or urgent care visit for a reaction.
Covers: Retatrutide and other research-use-only peptides
Source: The Ethos, May 2026
This describes what people do. It is not advice. The decision is yours.
What users report
On sale only since April 2026, too early for a fair summary of user reports.
What experts and influencers say
Recorded views, not a survey or scientific consensus. Cautions may concern misuse or unapproved products. Statements are paraphrased; check each source for context.
Supportive expert view
Led the 3,127-person phase 3 obesity trial. Hopes the pill can reach people shut out of treatment by the cost of injections and limited access to them.
Source: ConscienHealth, 2025-09
Sean WhartonWebsiteRecommends
Photo source: news.mcmaster.ca
Cautionary expert view
No sourced expert view in this category yet. See the full list for other perspectives.
See all views 4
Framed orforglipron as a pill that can be made at scale for a mass market with competitive weight loss, and said the programme was on plan after the phase 3 obesity results.
Source: ConscienHealth, 2025-09
David RicksInstagramRecommends
Money: Heads the company that makes the drug
Noted the pill avoids needles and cold storage, but weight loss is smaller than with injectable semaglutide or tirzepatide, heart outcomes are unstudied, and real-world use will decide its place.
Source: ConscienHealth, 2025-09
ConscienHealthSourceMixed view
Led the 3,127-person phase 3 obesity trial. Hopes the pill can reach people shut out of treatment by the cost of injections and limited access to them.
Source: ConscienHealth, 2025-09
Sean WhartonWebsiteRecommends
Photo source: news.mcmaster.ca
Reported about 11 percent average weight loss at the top strength over 72 weeks, acknowledged this is modestly below semaglutide trials, and said 5 to 10 percent stopped because of side effects.
Source: American College of Cardiology journal scan, 2025-09
ATTAIN-1 trial authorsSourceMixed view
More contextCase reports, watch and read, emerging uses and chemistry
Watch and read
Explainers, reporting and podcasts worth your time. Summaries are ours. No sellers.
Eli Lilly's obesity pill approved by FDA, setting up fierce competition with Novo Nordisk
Elaine Chen, STAT national biotech reporter
Reports the expedited FDA approval of orforglipron (Foundayo), how it lines up against Novo's Wegovy pill, and criticism of the fast-track voucher program.
Quick, sober account of the approval and the market fight.
How the 'holy grail' weight loss pill became a reality, and what comes next
Alex Hogan, STAT senior multimedia producer, with reporter Elaine Chen
Video explainer on why GLP-1 drugs were so hard to turn into pills, covering Novo's oral Wegovy and Lilly's pending orforglipron, and access questions.
Clear answer to why a pill took so long.
Diabetes Dialogue: Orforglipron Receives FDA Approval for Chronic Weight Management
A clinician-oriented news discussion of the FDA approval of orforglipron for chronic weight management.
Professional-audience take on what the approval means in practice.
When options run out
Uses people turn to when standard treatment has failed.
Option for people priced out of injections
- Who
- Adults with obesity who pay out of pocket, lack coverage for injectable GLP-1 drugs, or cannot manage needles and refrigeration.
- Evidence
- Phase 3 trial of 3,127 adults showed about 11 percent weight loss at top strength, less than injectables. US self-pay price was set well below injectable list prices.
Source: GLP1 Guide Substack, 2026-04
Legal last-resort routes
Expanded access (compassionate use)
For a serious or life-threatening condition with no comparable alternative and no trial you can join. Your physician asks the company for the drug, then files with FDA and an ethics board. The company can refuse. Costs are often not insured.
Right to Try
For a life-threatening condition after approved options are exhausted and no trial is open to you. The drug must have finished Phase 1 and be in active development. Your doctor asks the manufacturer directly. FDA does not review requests.
Source: FDA, Right to Try
Trial finders
Search ClinicalTrials.gov by condition or drug name, check eligibility and call the listed site. ResearchMatch is a free NIH-funded registry that lets researchers find you. Discuss risks with your own clinician before enrolling.
Source: NIH, finding a clinical trial
Personal import for serious conditions
FDA may not object when a US citizen imports up to about three months of a drug for a serious condition with no effective US treatment, with written personal-use confirmation and a US doctor's details. It is discretion, not a right.
Source: FDA, personal importation
Patient-specific compounding
When the approved product cannot meet a specific need of an identified patient, a prescriber can order a compounded version from a licensed pharmacy. Lower price alone does not qualify. Ingredients must be pharmaceutical grade.
Questions people ask
Is orforglipron a peptide?
No. It is a small molecule swallowed as a pill that switches on the GLP-1 receptor. It is in this book because it competes directly with the peptide drugs.
How much weight do people lose on Foundayo?
In ATTAIN-1, the top dose gave 12.4% average loss at 72 weeks among people who stayed on it and 11.1% counting everyone, against 2.1% on placebo.
Does Foundayo have to be taken on an empty stomach?
No. It is one tablet a day, at any time, with no food or water rules.
How much does Foundayo cost?
In the US, the maker's self-pay price started at $149 a month for the lowest dose. In the UK it is a private prescription only for now.
What are the side effects of orforglipron?
Nausea, diarrhea, vomiting and constipation, mostly while the dose is rising. In trials 6% to 10% of people stopped because of side effects, against 3% on placebo, and it carries a boxed warning for thyroid C-cell tumors.
Your notebook
Taking it? A ten-second daily check-in keeps a record of how you feel, to talk through with your clinician.
Sources
- Eli Lilly: FDA approves Foundayo (1 Apr 2026)
- Pharmaceutical Executive: EMA panel backs Foundayo (16 Oct 2026)
- MHRA: UK first in Europe to authorise orforglipron (10 Aug 2026)
- Fierce Pharma: Foundayo approval and boxed warning
- Eli Lilly: second-quarter 2026 results
- Pharmaceutical Journal: MHRA approves orforglipron (10 Aug 2026)
Structure: PubChem